Synactix Pharmaceutical Inc.

Anureet (sandy) Pabla
Student Innovation Fellow, 2014 – 2015
Tech Launch Arizona
Introduction

- B.S. Molecular and Cellular Biology
  - Minor in Business Administration
  - Class of 2015 (Graduating in two weeks!)

- What sparked my interest in commercialization
  - Summer job as a Pharmacy Technician
  - How did a drug end up on the shelf?
  - Theranos – the lab test, reinvented

at Theranos, we're working to shape the future of lab testing. Now, for the first time, our high-complexity CLIA-certified laboratory can perform your tests quickly and accurately on samples as small as a single drop.
Synactix Pharmaceuticals Inc.

- Founded June 2014
  - University of Arizona, department of pharmacology and toxicology
  - Drug Discovery, focus on the Medically underserved

- Dr. Hong-yu Li and Dr. Brendan Frett

- RET inhibitor which aids in the fight against cancer
  - Medullary Thyroid Cancer
  - 4% out of all thyroid cancers (600,000)
Technology and Research

- Small Molecule Benefits
  - Targets both RET and VEGFR-2
    - Active on both sites
  - Long shelf life
  - Very specific – fragment drug discovery
  - Water soluble
Comparable Drugs

- Same target, RET, VEGFR-2, MTC
- Clinical Trials for other cancers
- Toxic/ FDA approval Risks
Next Steps

- Start marketing the company more
- Develop the face of Synactix
- Keep options open
- Create goals and missions to help narrow in on what to do
The Fellows Experience

- Great real world experience in how processes like commercialization work
- Exposure to the fluidity of a startup
- Great introduction to the pharmaceutical industry
- Influential to my future career and plans after graduation
- Met and worked with wonderful people and other Innovation Fellows!